

June 24, 2021

## Santen to Present Latest Data on STN2000100 at COS 2021 and 9<sup>th</sup> WGC

Santen Pharmaceutical Co., Ltd. (Head Office in Osaka, hereinafter "Santen") announced today that some publications related to the glaucoma surgical device, STN2000100 (DE-128) will be presented at the Canadian Ophthalmological Society annual meeting (COS 2021, <u>https://cos2021.cossco.ca/sites/cos-sco/en/cos2021/</u>) from June 24 to 27, 2021, and 9<sup>th</sup> World Glaucoma E-congress (9<sup>th</sup> WGC, <u>https://worldglaucomacongress.org/</u>) from June 30 to July 3, 2021.

STN2000100 has been launched in Europe as *PRESERFLO MicroShunt* and Santen successively filed for marketing approval in Asia. Santen submitted the Premarket Approval (PMA) application in the U.S. In the conferences, some presentations including two-year data from a clinical study in the U.S. and Europe, INN-005, will be conducted.

In addition, Glaukos Corporation (San Clemente, CA, U.S.) is responsible for developing and selling products in the Americas, Australia, and New Zealand.

Session title	Date and time	Presentation title
Glaucoma	Jun 27, 2021	Safety and effectiveness of MicroShunt implantation versus
Intervention:	15:35–15:40 (EDT)	trabeculectomy: 2-year results from a randomized,
Current Dilemmas		multicentre study
and Future		
Outlook		
Glaucoma	Jun 27, 2021	Safety outcomes of MicroShunt implantation versus
Intervention:	15:40–15:45 (EDT)	trabeculectomy in patients with primary open-angle
Current Dilemmas		glaucoma
and Future		
Outlook		
Virtual Exhibition	N/A	A 2-year pooled analysis of the MicroShunt in patients with
Hall	(Poster)	primary open-angle glaucoma

Presentation topics at COS 2021

Presentation topics at 9th WGC

Poster ID and topic	Availability	Presentation title
P-431	Available	MicroShunt versus trabeculectomy in primary open-angle
Surgery and	throughout	glaucoma: Visual performance outcomes from baseline to
Wound Healing	congress (June 30	Year 1
	to July 3) and on	
	the WGC platform	
	until Dec 31, 2021	

Contact: Investor Relations Group Santen Pharmaceutical Co., Ltd. E-mail: <u>ir@santen.com</u>